Consequently, the characterization of senescence-associated biomarkers, including lamin B1, should facilitate the assessment of clinical senescence in breast cancer patients, allowing for the selection of more effective therapeutic approaches [32,34,37]. This evidence concerns the gene LMNB1 and breast carcinoma.